A5102813984- Cancer Immunotherapy and Biomarkers
- Venous Thromboembolism Diagnosis and Management
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Head and Neck Cancer Studies
- Cutaneous Melanoma Detection and Management
- Inflammatory Biomarkers in Disease Prognosis
- Renal cell carcinoma treatment
- Nonmelanoma Skin Cancer Studies
- Polyomavirus and related diseases
- Lymphoma Diagnosis and Treatment
- Chronic Disease Management Strategies
- Histone Deacetylase Inhibitors Research
- Cancer Diagnosis and Treatment
- Viral-associated cancers and disorders
- Cervical Cancer and HPV Research
- PARP inhibition in cancer therapy
- Migration, Aging, and Tourism Studies
- Employment and Welfare Studies
- Retirement, Disability, and Employment
- Cancer Genomics and Diagnostics
- Brain Metastases and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Primary Care and Health Outcomes
- Photodynamic Therapy Research Studies
Cleveland Clinic
2017-2025
Dana-Farber Cancer Institute
2021-2024
Brigham and Women's Hospital
2024
Harvard University
2024
Cancer Institute (WIA)
2020
University of Pittsburgh
2018
Geriatric (aged ≥80 years) patients are historically underrepresented in cancer clinical trials. Little is known about the efficacy of immune checkpoint inhibitors (ICIs) geriatric patients. These agents associated with immune-related adverse events (irAEs), which may be particularly morbidity this population.To provide insight into outcomes and safety ICIs among cancer.A Multicenter, international retrospective study 928 different tumors treated single-agent between 2010 to 2019 from 18...
Background Thromboembolism (TE) in cancer significantly contributes to morbidity and mortality. Little is known about the incidence of arterial TE (ATE) venous (VTE) patients with melanoma on immune checkpoint inhibitor (ICI) therapy. Methods We conducted a retrospective cohort study receiving ICI from July 2015 through December 2017 at Cleveland Clinic. TE, including VTE events deep thrombosis, pulmonary embolism, visceral vein ATE myocardial infarction, stroke, peripheral or transient...
•The immunotherapeutic treatment landscape for patients with high-risk melanoma has increased in complexity at a rapid pace.•Neoadjuvant immunotherapy an increasingly important role surgically resectable melanoma.•Identifying the most effective therapeutic regimen adjuvant setting will require additional randomized studies.•Novel checkpoint inhibitors, personalized vaccines, and better predictive tools are on horizon. The majority of who diagnosed cutaneous candidates surgical resection thus...
Older patients have similar immune checkpoint inhibitor efficacy and rates of adverse events as younger patients, but appear to decreased tolerability, particularly in the oldest patient cohort (>80 years), often leading early cessation therapy. We aimed determine whether discontinuation impacts anti-PD-1 therapy ≥80 years old. In this retrospective, multicenter, international study, we examined 773 with 4 tumor types who were at least 80 old treated determined response rate, overall...
To evaluate factors affecting the utilization of immunotherapy and to stratify results based on approval ipilimumab in 2011 programmed death-1 inhibitors 2014, an analysis available data from National Cancer Database (NCDB) was performed.The NCDB analyzed identify patients with stage IV melanoma 2004 2016. Patients were categorized during time periods 2004-2010, 2011-2014, 2015-2016. Overall survival (OS) by Kaplan-Meier, log-rank, Cox proportional hazard models; IO status using logistic...
9585 Background: Neoadjuvant immunotherapy is a potential curative approach to patients with locally advanced cutaneous squamous cell carcinoma (cSCC) that offers an attractive alternative traditional, often morbid surgery and/or radiation. In this study, we report our initial institutional experience treating primary monotherapy (PRIMO) and reserving or radiation for progression only. Methods: Patients recurrent cSCC (AJCC 8 T3-4 node positive in-transit metastases) in whom surgical...
To evaluate factors affecting the utilization of immunotherapy and to stratify results based on approval ipilimumab in 2011 PD-1 inhibitors 2014, an analysis available data from National Cancer Database (NCDB) was performed. Stage IV melanoma patients were identified. Effects overall survival (OS) assessed using Kaplan–Meier curves Cox proportional hazards model. A total 19 233 analyzed 1998 received immunotherapy. Between 2013, 18.6 28.9% immunotherapy, respectively. Patients who 2013 had a...
94 Background: VTE in cancer significantly contributes to morbidity and a worse overall prognosis. Little is known about the incidence of melanoma pts receiving IO. This study aims assess on IO, interrogate potential association with specific therapies, ascertain its prognostic utility. Methods: We conducted retrospective cohort who received any IO including ipilimumab (ipi), nivolumab (nivo) or pembrolizumab (pembro) from July 2015 December 2017 at Cleveland Clinic. deep venous thrombosis...
TPS10082 Background: Melanoma has a response rate of 10-15% with anti-PD-1 re-challenge in the refractory setting. Newer targeted therapies melanoma are needed, especially once patients progress on immune checkpoint inhibitor (ICI) therapy. Analysis TCGA and Cleveland Clinic’s Gross Family Registry reveals that significant proportion (~40%) possess somatic (31.6%) or germline (TCGA: 4.2%; Registry: 8.3%) mutations homologous recombination repair genes, which may serve as therapeutic target....
Abstract Novel therapies are needed for anti-PD-1 refractory metastatic melanoma. Few rationally target biologically selected subpopulations of In the Cleveland Clinic Familial Melanoma Registry, a high rate germline mutations in proteins that regulate DNA repair were seen. PARP inhibitors can lead to synthetic lethality and clinical benefit patients with BRCA or associated damage (“BRCAness phenotype”). Additionally, preclinical models have shown STING activation, raising hypothesis...
Background In the era of immune checkpoint blockade, role cancer vaccines in priming has provided additional potential for therapeutic improvements. Prior studies have demonstrated delayed type hypersensitivity and anti-tumor immunity with engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF). The safety, efficacy GM-CSF secreting vaccine patients previously treated stage III or IV melanoma needs further investigation. Methods this phase II trial, excised lymph node...